Investor relations
With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Press Releases
Sedana Medical AB's Interim report January-March 2024
Regulatory
Off to a strong start with record sales in Q1
Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US
Non-regulatory
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSP…
Notice of Annual General Meeting in Sedana Medical
Regulatory
The board of directors of Sedana Medical AB (publ) has resolved to convene an annual general meeting…
Financial Calendar
| Annual Report 2023 | 15 April 2024 | 21:00 |
| Interim Report Q1 2024 | 25 April 2024 | 07:00 |
